Tirzepatide
Also known as: Mounjaro · Zepbound · LY3298176
A dual GLP-1 and GIP receptor agonist representing the next generation of metabolic peptides. Achieves greater weight loss than semaglutide with average reductions of 20-22.5% body weight.
Mechanism of Action
Tirzepatide acts as an agonist at both GLP-1 and GIP receptors. The dual action provides synergistic metabolic effects: GLP-1 reduces appetite while GIP enhances the incretin effect.
Amino Acid Sequence (39 AAs)
Proprietary 39-AA backbone (GIP-GLP-1 hybrid) with C20 fatty diacid
Benefits
- Superior weight loss vs. semaglutide (20-22.5% body weight)
- Dual GLP-1/GIP receptor activation
- Significant HbA1c reduction
- Improved cardiovascular risk factors
- Reduced visceral adiposity
- Weekly dosing
Side Effects & Risks
- Nausea, vomiting, diarrhea
- Decreased appetite
- Constipation
- Potential pancreatitis
- Hypoglycemia
- Muscle mass reduction
Where to Buy Tirzepatide
5 options across 3 vendors · Sorted cheapest first · All include direct product link
From
$79.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies3 trials
Tirzepatide versus Semaglutide for Weight Reduction (SURMOUNT-5)
Tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks.
SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity
First head-to-head trial of tirzepatide vs semaglutide in obesity. Tirzepatide 15mg produced 20.2% weight loss vs 13.7% with semaglutide 2.4mg (treatment difference -6.5 pp; 95% CI -7.6 to -5.4; p<0.0001) over 72 weeks.
Primary Outcome
Weight change from baseline
95% CI
-7.6 to -5.4
p-value
<0.0001
Semaglutide
13.7%
Tirzepatide
20.2%
≥20% Responders
32.8% (tirzepatide) vs 14.4% (sema)
Treatment Difference
-6.5 percentage points
SURMOUNT-1: Tirzepatide for Obesity
In 2,539 adults with obesity (no T2D), tirzepatide 5mg/10mg/15mg produced weight loss of 16.0%/21.4%/22.5% vs -2.4% placebo at 72 weeks (all p<0.001). At 15mg, 63% achieved ≥20% weight loss vs 1.3% placebo.
Primary Outcome
Weight change from baseline at 72 weeks
p-value
<0.001 all doses
Placebo
-2.4%
Tirzepatide 5mg
-16.0%
Tirzepatide 10mg
-21.4%
Tirzepatide 15mg
-22.5%
20pct Responders 15mg
63% vs 1.3% placebo
Molecular Structure
- CAS Number
- 2023788-19-2
- PubChem CID
- 168009818
- Molecular Weight
- 4,813 Da
- Mol. Formula
- C225H348N48O68
- Amino Acids
- 39-AA peptide
- Wikipedia
- View article
Research Protocol
- Dose Range
- 2.5–15 mg
- Frequency
- Once weekly subcutaneous injection
- Cycle
- Ongoing / chronic
- Half-Life
- 5 days
- Routes
- subcutaneous injection
- Notes
- Titrate from 2.5mg/week up by 2.5mg every 4 weeks to maximum 15mg.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
More in Weight Management
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.